PQUS0.110%
as of Jul 21
SYK
GrowthSTRYKER CORPORATION
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products.
Close · 3M
-12.78%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals1
Win rate100% (1/1)
Avg buy return+12.94%
PQUS · Weight decrease · 2d
The observed two-step decrease in Stryker's weight from 0.13% to 0.11% within PQUS, after a stable period at 0.13%, reflects a measured adjustment by Pictet Asset Management's AI ranking system. This gradual reduction, rather than an abrupt shift, aligns with the fund's style of US large-cap investing with measured turnover and periodic rebalancing, preventing daily volatility from driving significant portfolio changes. Given Stryker's valuation metrics—a PER of 37.25 and PBR of 6.0—combined with its price trading at 78% of its 52-week high and an 18.5% decline over 90 days, the AI system likely recalibrated the stock's attractiveness. This methodical repositioning suggests the AI is integrating both performance and valuation signals, alongside sector-balance and concentration rules, within its structured rebalancing process.
weight 0.130% → 0.110% (-0.020 pp)·stock up 11.3% in the 30 days before
Jul 2·entry $326.54·now $319.14
-2.27%
since Jul 2
PQUS · Weight increase · 2d
The AI ETF likely initiated a consecutive weight increase in SYK by detecting strengthening positive momentum or new catalysts reinforcing its solid revenue growth and strong ROE within the healthcare sector, prioritizing these dynamic factors over its high valuation multiples. For a retail investor, this signals an AI fund's increased confidence in a quality growth stock, but given the elevated PER and PBR, independent research into the specific drivers and potential risks remains critical before investing.
weight 0.130% → 0.150% (+0.020 pp)·stock down 15.8% in the 30 days before
May 10·entry $282.58·now $319.14Chased
+12.94%
since May 10
QRFT · Exit · 1d
The AI ETF likely divested from SYK due to its high valuation metrics, specifically its elevated P/E of 33.89 and P/B of 6.0, which likely triggered the fund's internal valuation models for removal given the stock's relatively slower revenue growth. For retail investors, this illustrates that even fundamentally sound companies can be deemed overvalued by algorithmic strategies, emphasizing the importance of considering price-to-earnings and price-to-book ratios alongside growth when making investment decisions.
weight 0.250% → 0 (exited)·stock down 12.3% in the 30 days before
May 4·entry $290.88·now $319.14
+9.72%
since May 4
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of May 11
One AI ETF (PQUS) is increasing its weight in Stryker, indicating a positive sentiment, while another (QRFT) recently exited its position. This mixed AI ETF activity contrasts with the value-investing framework's 'Fail' verdict, which is primarily driven by the current premium valuation that leaves no margin of safety.
- Circle of CompetenceStryker's position in stable medical technology sectors with predictable demand allows for reasonable projection of ten-year cash flows.
- Economic MoatThe company benefits from high switching costs for medical professionals, strong brand reputation, regulatory barriers to entry, and economies of scale in R&D and distribution.
- ManagementInformation regarding management's candor, capital allocation discipline, and skin in the game cannot be assessed from the provided data.
- Financial HealthInsufficient data, specifically for 10-year average ROE, operating margin trends, manageable debt levels, and owner earnings, prevents a comprehensive financial health assessment.
- Margin of SafetyWith a high P/E ratio of 32.76 and EV/EBITDA of 26.4, the current price does not offer a defensible margin of safety relative to a conservative estimate of intrinsic value.
Stryker appears to be a high-quality business operating within a predictable circle of competence and protected by a strong economic moat. However, a comprehensive assessment of management and financial health is hindered by a lack of data, and the current valuation multiples indicate the stock trades at a premium, preventing a crucial margin of safety.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.